医学
卡铂
贝伐单抗
内科学
肿瘤科
彭布罗利珠单抗
人口
放化疗
培美曲塞
化疗
实体瘤疗效评价标准
癌症
外科
顺铂
临床研究阶段
免疫疗法
环境卫生
作者
Krishnansu S. Tewari,Nicoletta Colombo,Bradley J. Monk,Coraline Dubot,M. Valeria Cáceres,Kosei Hasegawa,Ronnie Shapira‐Frommer,Pamela Salman,Eduardo Yáñez,Mahmut Gümüş,Mivael Olivera,Vanessa Samouëlian,Vincent Castonguay,Alexander Arkhipov,Cumhur Tekin,Kan Li,Sarper Toker,Stephen J. O’Keefe,Domenica Lorusso
出处
期刊：JAMA Oncology
[American Medical Association]
日期：2023-12-14
卷期号：10 (2): 185-185
被引量：28
标识
DOI：10.1001/jamaoncol.2023.5410
摘要
The KEYNOTE-826 randomized clinical trial showed statistically significant and clinically meaningful survival benefits with the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer. Treatment effects in patient subgroups of the study population are unknown.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
SYLH
ceeray23
热心市民小红花
杳鸢
iNk
LaTeXer
herococa
哇哇哇哇我
pluto
Tourist
GingerF
小豆豆
七月流火
1101592875
奶黄包
昏睡的蟠桃
quhayley
鸣笛
清风
eric888
皖公网安备34019202002308
